peracetylated maltose | 23973-20-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: peracetylated maltose
• 英文别名: Maltose octaacetate；[4,5,6-triacetyloxy-3-[3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate
• CAS: 23973-20-8
• 化学式: C₂₈H₃₈O₁₉
• 分子量: 678.598
• InChiKey: WOTQVEKSRLZRSX-UHFFFAOYSA-N

物化性质

• 沸点：
  683.1±55.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  47
• 可旋转键数：
  20
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  238
• 氢给体数：
  0
• 氢受体数：
  19

反应信息

• 作为反应物：
  描述：

  3-butyl-N-(2-hydroxyethyl)-3-phenylheptanamide 、 peracetylated maltose 在 三氟化硼乙醚 作用下， 以62%的产率得到
  参考文献：
  名称：

  Amphiphiles for protein solubilization and stabilization

  摘要：

  该发明提供了用于操纵膜蛋白的两性分子。这些两性分子可以具有碳水化合物衍生的亲水基团以及在亲水部分和/或疏水部分中的分支点。这种两性分子可用作溶解和稳定膜蛋白的洗涤剂，包括从细菌膜中获得的光合蛋白超组装体。

  公开号：

  US08263754B2

文献信息

• MODIFIED OLIGONUCLEOTIDES AND COMPOUND THAT CAN BE USED FOR SYNTHESIZING SAME
  申请人：Guangzhou Ribobio Co., Ltd.

  公开号：EP3677588A1

  公开（公告）日：2020-07-08

  The present invention falls within the field of biomedical technology, and in particular relates to modified oligonucleotides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present invention also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

  本发明属于生物医学技术领域，尤其涉及修饰的寡核苷酸和可用于合成修饰的寡核苷酸的化合物以及修饰寡核苷酸的方法。本发明还涉及使用经修饰的寡核苷酸预防和/或治疗受试者与肝脏有关的疾病。
• Sulfated-glycolipids as adjuvants for vaccines
  申请人：National Research Council of Canada

  公开号：US10647737B2

  公开（公告）日：2020-05-12

  A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid:uncharged glycolipid) and which induce a protective immune response, including CD8+ and CD4+ T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50.

  本发明描述了一种合成带电糖脂，它包括一个硫酸化的糖基，通过β连接与古核脂质的甘油骨架的树 Sn-1 羟基共价连接。合成的带电糖脂包括式 I 的化合物，其中 n 是 0 或 1；R 是氢或羟基；Y 是氢或硫酸基团，至少一个 Y 是硫酸基团；还包括其药学上可接受的盐。硫酸化糖脂可产生稳定的弓形体，其摩尔比为 100:0 至 30:70（硫酸化糖脂：无电荷糖脂），可诱导保护性免疫反应，包括 CD8+ 和 CD4+ T 细胞反应。由所述硫酸化糖脂组成的弓形体具有理想的佐剂特性，特别是当与不带电荷的糖脂以约 50:50 的摩尔%比例混合时。
• Gel formulations for local drug release
  申请人：TECHNICAL UNIVERSITY OF DENMARK

  公开号：US11065201B2

  公开（公告）日：2021-07-20

  The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.

  本发明涉及一种包含非水溶性碳水化合物的组合物，其中至少50%的非水溶性碳水化合物是选自乳糖、麦芽糖、树海糖、棉子糖、葡糖胺、半乳糖胺、乳糖胺的衍生物、或具有至少两个吡喃糖糖单位的二糖、三糖、四糖或其混合物的衍生物，其中的组合物在注入人体或动物体内前为液体，在注入人体或动物体内后粘度增加超过 1,000 厘泊 (cP)，可用作药物。
• Device manufacturing method and device
  申请人：Zuilhof Teinus Johannes

  公开号：US20070178707A1

  公开（公告）日：2007-08-02

  A method for patterning a polished silicon surface is disclosed, the method including steps leading to an organic monolayer on at least a part of the silicon surface, the monolayer being functionalized in specific desired locations. The method can be used to produce a device comprising one or more FET structures, the gate of the FET being formed by the functionalized organic monolayer. The functionalized monolayer preferably contains oligosaccharides or oligopeptides which are capable of interacting with biological substance, such that the device acts as a bio-sensor.
• SULFATED-GLYCOLIPIDS AS ADJUVANTS FOR VACCINES
  申请人：National Research Council of Canada

  公开号：US20170158728A1

  公开（公告）日：2017-06-08

  A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid: uncharged glycolipid) and which induce a protective immune response, including CD8 + and CD4 + T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50.

表征谱图